C2N Diagnostics, a diagnostics company specializing in blood tests for Alzheimer’s disease, is expanding its services to more than seven countries, backed in part by a $10 million investment from South Korea’s Samsung Group, a global conglomerate with businesses spanning electronics, construction, and biotechnology.
The company announced on August 7 that it has partnered with six global healthcare providers: Accuserv Diagnostic Center (Philippines), Archerfish Precision Diagnostics (Singapore and Southeast Asia), Codex Genetics (Hong Kong), Dr. Dang’s Lab (India), Medical Link (Israel), and Millennium Labs (Costa Rica and Mexico).
Through these partnerships, C2N will offer blood-based diagnostic services such as PrecivityAD2™, which can detect early signs of Alzheimer’s disease and other causes of cognitive decline through a simple blood draw. The expansion targets countries with limited diagnostic infrastructure.
C2N’s proprietary technology measures and analyzes trace amounts of protein biomarkers in the blood, enabling advanced Alzheimer’s diagnostics and participation in clinical trials for treatments and other central nervous system disorders. Last month, the company introduced two new plasma biomarkers—C2N eMTBR-tau243 and C2N p-tau MAA—to further enhance early detection capabilities.
Samsung C&T, through its life sciences fund co-established with Samsung Biologics, Samsung Bioepis, and Samsung Venture Investment, invested $10 million in C2N earlier this year, citing the company’s strong technological capabilities and potential in the growing diagnostics market.
